These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure. Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357 [No Abstract] [Full Text] [Related]
4. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study]. Burnier M; Waeber B; Hess O; Lüscher T Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371 [No Abstract] [Full Text] [Related]
5. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET. Schindler C Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424 [TBL] [Abstract][Full Text] [Related]
6. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension]. MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381 [No Abstract] [Full Text] [Related]
7. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection]. MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984 [No Abstract] [Full Text] [Related]
8. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?]. MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331 [No Abstract] [Full Text] [Related]
9. Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Baumhäkel M; Böhm M Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045 [TBL] [Abstract][Full Text] [Related]
17. Telmisartan, ramipril, or both in patients at high risk of vascular events. Büchner N; Banas B; Krämer BK N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521 [No Abstract] [Full Text] [Related]
18. Study at up to 700 sites will build on landmark HOPE trial. Cardiovasc J S Afr; 2001; 12(2):127-30. PubMed ID: 11474703 [No Abstract] [Full Text] [Related]
19. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection. Mancia G; Unger T; Zanchetti A J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549 [No Abstract] [Full Text] [Related]